Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02582359 · ClinicalTrials.gov registry record · Phase 1
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT02582359: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT02582359 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 39 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02582359, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This research study is evaluating drugs called Millennium 9708 (referred to as MLN9708) in combination with standard therapy for acute myeloid leukemia (AML) consisting of daunorubicin and cytarabine as a possible treatment for the patient AML.
Primary Outcome
Safety of MLN9708 in induction
Interventions
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG MLN9708
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-01 |
| Est. Completion | 2022-04 |
| Phase | Phase 1 |
What the finished NCT02582359 record still lists
NCT02582359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 3 interventions - of which Cytarabine is the first listed.
NCT02582359 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02582359 about?
NCT02582359 is a clinical study titled "MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age". This research study is evaluating drugs called Millennium 9708 (referred to as MLN9708) in combination with standard therapy for acute myeloid leukemia (AML) consisting of daunorubicin and cytarabine as a possible treatment for the patient AML.
What is the current status of trial NCT02582359?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2016-01. Estimated completion is 2022-04.
What interventions are being tested in trial NCT02582359?
The interventions under investigation include: Cytarabine (DRUG), Daunorubicin (DRUG), MLN9708 (DRUG).
Who is sponsoring clinical trial NCT02582359?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02582359's enrollment target sits among peer trials
39 1191st of 2000 higher than 804 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia